The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study

•Clobazam is a well-tolerable drug with a high seizure-free rate (18.7 %) and a significant seizure reduction rate (57.3 %)•A positive response was observed in focal-onset (62.3 %) and generalized-onset (57.4 %) seizures.•The highest negative response and tolerance were observed in the developmental/epileptic encephalopathies group•Reversible benefit may occur with considerable seizure recurrence in 12.7 % of cases (tolerance).•Negative response and reversible benefit rates were higher in epileptic children with genetic and metabolic causes.